AU2020257283B2 - Modified anti-PD-L1 antibodies and methods and uses for treating a neurodegenerative disease - Google Patents

Modified anti-PD-L1 antibodies and methods and uses for treating a neurodegenerative disease

Info

Publication number
AU2020257283B2
AU2020257283B2 AU2020257283A AU2020257283A AU2020257283B2 AU 2020257283 B2 AU2020257283 B2 AU 2020257283B2 AU 2020257283 A AU2020257283 A AU 2020257283A AU 2020257283 A AU2020257283 A AU 2020257283A AU 2020257283 B2 AU2020257283 B2 AU 2020257283B2
Authority
AU
Australia
Prior art keywords
seq
antibody
modified anti
heavy chain
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020257283A
Other languages
English (en)
Other versions
AU2020257283A1 (en
Inventor
Kuti BARUCH
Carol DAVID
Jan Egebjerg
Michal Eisenbach-Schwartz
Allan Jensen
Berit Olsen Krogh
Ester Yoles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Immunobrain Checkpoint Inc
Original Assignee
Yeda Research and Development Co Ltd
Immunobrain Checkpoint Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Immunobrain Checkpoint Inc filed Critical Yeda Research and Development Co Ltd
Publication of AU2020257283A1 publication Critical patent/AU2020257283A1/en
Application granted granted Critical
Publication of AU2020257283B2 publication Critical patent/AU2020257283B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020257283A 2019-04-19 2020-04-19 Modified anti-PD-L1 antibodies and methods and uses for treating a neurodegenerative disease Active AU2020257283B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962836247P 2019-04-19 2019-04-19
US62/836,247 2019-04-19
EP19170438.6A EP3725370A1 (en) 2019-04-19 2019-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP19170438.6 2019-04-19
PCT/US2020/028900 WO2020215049A1 (en) 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Publications (2)

Publication Number Publication Date
AU2020257283A1 AU2020257283A1 (en) 2021-12-16
AU2020257283B2 true AU2020257283B2 (en) 2026-04-02

Family

ID=66240002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020257283A Active AU2020257283B2 (en) 2019-04-19 2020-04-19 Modified anti-PD-L1 antibodies and methods and uses for treating a neurodegenerative disease

Country Status (14)

Country Link
US (4) US10995141B2 (cg-RX-API-DMAC10.html)
EP (2) EP3725370A1 (cg-RX-API-DMAC10.html)
JP (2) JP7752050B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220002972A (cg-RX-API-DMAC10.html)
CN (1) CN114007645B (cg-RX-API-DMAC10.html)
AU (1) AU2020257283B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021020947A2 (cg-RX-API-DMAC10.html)
CA (1) CA3137143A1 (cg-RX-API-DMAC10.html)
CL (2) CL2021002735A1 (cg-RX-API-DMAC10.html)
IL (1) IL287008A (cg-RX-API-DMAC10.html)
MX (1) MX2021012783A (cg-RX-API-DMAC10.html)
SG (1) SG11202110990RA (cg-RX-API-DMAC10.html)
WO (1) WO2020215049A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202109173B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200029627A (ko) * 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
AU2022219986A1 (en) * 2021-02-14 2023-08-31 Prothena Biosciences Limited Methods of using antibodies recognizing tau
CN115073599B (zh) * 2021-03-16 2023-04-28 北京天广实生物技术股份有限公司 结合pd-l1的抗体及其用途
WO2024233694A2 (en) * 2023-05-08 2024-11-14 Immunobrain Checkpoint Inc. METHODS FOR REDUCING IgG ANTIBODY TRANSFER FROM MOTHER TO UNBORN BABY DURING IMMUNOTHERAPY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US9617338B1 (en) * 2016-06-20 2017-04-11 Kymab Limited Antibodies and immunocytokines
US20170355770A1 (en) * 2016-06-13 2017-12-14 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AU2007319806A1 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of TIM-3 modulators
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
CA2745439C (en) 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2990678C (en) 2009-11-06 2021-08-31 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
US8835613B2 (en) 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
CA2819829A1 (en) 2010-12-01 2012-06-07 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
EP2744830A4 (en) 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP2015525781A (ja) 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の調節
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
WO2014045305A1 (en) 2012-09-21 2014-03-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2014059251A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US8877202B2 (en) 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
MX428954B (es) 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
EP3650038A1 (en) 2013-06-19 2020-05-13 Massachusetts Institute of Technology In vivo targeting of cells with ligand-conjugated particles
WO2014205199A2 (en) 2013-06-22 2014-12-24 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
SG11201601283PA (en) 2013-08-22 2016-03-30 Queensland Inst Med Res Immunoreceptor modulation for treating cancer and viral infections
MX2016002265A (es) 2013-08-22 2016-12-16 The Council Of The Queensland Inst Of Medical Res Modulacion de inmunoreceptor para tratar cancer e infecciones virales.
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
WO2015084721A1 (en) 2013-12-02 2015-06-11 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
MX371187B (es) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Péptidos terapéuticos.
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
WO2017042633A2 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2019013132A (es) * 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
US20200199247A1 (en) * 2017-06-07 2020-06-25 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
CN109467603B (zh) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20170355770A1 (en) * 2016-06-13 2017-12-14 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
US9617338B1 (en) * 2016-06-20 2017-04-11 Kymab Limited Antibodies and immunocytokines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DENG R. ET AL: "Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor", MABS, vol. 8, no. 3, 26 February 2016, pages 593 - 603 *
KIM J-K ET AL: "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 29, no. 9, 1 September 1999, pages 2819 - 2825 *
LIN J. ET AL, CANCER BIOLOGY & THERAPY, vol. 14, no. 11, 1 November 2013, pages 1032 - 1038 *
ROSENZWEIG N. ET AL: "PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model", NATURE COMMUNICATIONS, vol. 10, no. 1, 28 January 2019 *
WANG X. ET AL: "IgG Fc engineering to modulate antibody effector functions", PROTEIN & CELL, vol. 9, no. 1, 6 October 2017, pages 63 - 73 *

Also Published As

Publication number Publication date
ZA202109173B (en) 2023-04-26
JP2022529789A (ja) 2022-06-24
BR112021020947A2 (pt) 2022-04-05
US11732046B2 (en) 2023-08-22
CN114007645B (zh) 2026-03-27
SG11202110990RA (en) 2021-10-28
US20200332011A1 (en) 2020-10-22
MX2021012783A (es) 2022-02-10
JP7752050B2 (ja) 2025-10-09
EP3725370A1 (en) 2020-10-21
IL287008A (en) 2021-12-01
US20260193358A1 (en) 2026-07-09
CL2024002016A1 (es) 2024-10-18
WO2020215049A1 (en) 2020-10-22
CN114007645A (zh) 2022-02-01
CA3137143A1 (en) 2020-10-22
CL2021002735A1 (es) 2022-05-20
US20210221893A1 (en) 2021-07-22
KR20220002972A (ko) 2022-01-07
EP3955961A4 (en) 2023-06-14
AU2020257283A1 (en) 2021-12-16
EP3955961A1 (en) 2022-02-23
JP2025114621A (ja) 2025-08-05
US10995141B2 (en) 2021-05-04
US20240052038A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
US20240052038A1 (en) Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease
US11180545B2 (en) Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
JP7303126B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP2023109927A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
JP7240335B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
US11958905B2 (en) Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
EA036499B1 (ru) Моноклональное антитело, которое способно специфически связываться с альфа-синуклеином человека
WO2019126756A9 (en) Heavy chain antibodies binding to cd22
WO2021247397A2 (en) Methods and compositions for enhancing the immune system
KR20180037984A (ko) 개선된 결합 특징, 기능적 특징 및 안전성 특징을 구비한 항-cd154 항체 및 인간 면역요법에서의 용도
CN111763259B (zh) 抗cd40抗体及其用途
AU2022270543A1 (en) Bispecific antibody specifically binding to cd47 and pd-l1
CN118403155A (zh) 用于治疗脊髓损伤和疼痛的抗反义导向分子a（rgma）拮抗性抗体
JP2023534779A (ja) 抗セラミド抗体
EP4518896A1 (en) Compositions and methods for treating ocular diseases
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof
CN119264263A (zh) 靶向pd-1和lag3的双特异性抗体及其用途
HK40036534A (en) Heavy chain antibodies binding to cd22
HK40036534B (en) Heavy chain antibodies binding to cd22
NZ795790A (en) Anti-BCMA heavy chain-only antibodies
CA3006092A1 (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)